The risk of death was highest in the first year of follow-up.

– In summary, we found increased[ risks] for death in patients with biopsy confirmed celiac disease, inflammation, and latent celiac disease, although absolute risks were small people undergoing small intestinal biopsy in childhood had increased[ risks] for death. In celiac disease and malignancy were the main causes of death in celiac disease, the authors write. JAMA 2009;. 302[ 11]:1171 – 1178th.. The risk of death was highest in the first year of follow-up, with celiac disease with a 2.8 – fold increased risk of death, inflammation with a 4.7 – fold increase, and latent celiac disease with a 1.8 – fold increase together. After the first year of follow-up, decreased these figures.

Research on other inflammatory disorders suggests that inflammation may be associated with increased mortality, 13,306 has not been investigated for nonspecific inflammation in the small intestine. .. Jonas F. In February 2008, moved to Sweden to examine the overall risk of death in people with celiac disease, celiac disease and inflammation , data from the biopsies was divided into three groups divided inflammation . And individuals with latent celiac disease (n= 3 latent celiac disease positive positive celiac disease serology in individuals with normal intestinal mucosa through linkage with the Swedish Total population register, the researchers estimated the risk of death through August 2008, compared with age-and gender-matched controls from the general population.

Celiac disease is an immune-mediated disease caused by gluten exposure in genetically susceptible individuals, which is initiated at about 1 % of the Western population, according to background information in the article.The primary endpoint is late lumen loss, such angiography at nine months. Secondary endpoints include MACE and volumetric blockage. The intravascular ultrasound , Optical Coherent Tomography and physiologic sub research will well as probably to be carried out. – We are accelerating the pivotal trial will receive the results by VESTAsync in our pilot study after nine months of patients follow-up and potential to reliability in the currently marketed medication – eluting stents address the use of polymers to provide drugs, said Dr. Mark Landy, President and Chief Executive Officer of MIV Therapeutics. We stent is a polymeric – free, nano, microporous hydroxy apatite stent of, which ability of that, an organic material, short term a far smaller effective dosage the drug did in fact 60 % of less.

With of UBC and has received Government grant of the research program on ‘Development of novel Drug Eluting Composite coating on cardiovascular Stents, ‘below National Research Council of – Industrial Research Assistance Program of the product the Company is expected to complete to its active eluting of research and development Programme and achieve commercialization of products. MIT intellectual property portfolio including patents University of British Columbia and exclusively licensed to MIV. Key patent applications while in different countries across the world more protect the commercial exclusivity of MIV’s inventions on the global market.